Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.52 |
| ▸ | AKT2 | P31751 | 11/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.39 |
| ▸ | FECH | P22830 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376128 | 0.88 | AKT1 (0.49) | AKT1AKT2KCNH2 | |
| SCHEMBL3505849 | 0.83 | AKT1 (0.43) | AKT1AKT2KCNH2HPGDRXFP1 | |
| SCHEMBL3504691 | 0.82 | AKT1 (0.47) | AKT1AKT2KCNH2HPGDRXFP1 | |
| SCHEMBL2278868 | 0.81 | AKT1 (0.48) | AKT1AKT2KCNH2HPGDRXFP1 | |
| SCHEMBL2279249 | 0.80 | ALDH1A1 (0.47) | AKT1AKT2KCNH2LMNAMAPT | |
| SCHEMBL2287763 | 0.80 | AKT1 (0.47) | AKT1AKT2KCNH2HPGDRXFP1 | |
| SCHEMBL2283339 | 0.80 | KDM4E (0.49) | AKT1AKT2KCNH2HPGDRXFP1 | |
| SCHEMBL14796819 | 0.79 | AKT1 (0.47) | AKT1AKT2KCNH2HPGDRXFP1 | |
| SCHEMBL2281677 | 0.79 | AKT1 (0.46) | AKT1AKT2KCNH2HPGDLMNA | |
| SCHEMBL2281499 | 0.78 | AKT1 (0.46) | AKT1AKT2KCNH2HPGDRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222321-A1 | Inhibitors of akt activtiy | PIK3CA, PIK3CD, INPP5D | AKT1 8/4885AKT2 4/4885KCNH2 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.